SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Blackstone Commits $750 Million to Fund J&J Retinal Drug Trials

Blackstone commits $750 million to Johnson & Johnson's Phase 3 trials of retinal disease drug OLN324.

BXJNJ

Related stories